Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB S6 500) in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Batiraxcept (Primary) ; Paclitaxel
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Registrational; Therapeutic Use
Acronyms AXLerate-OC; PROC
Sponsors Aravive

Most Recent Events

04 Jun 2024 Results(n=366) demonstrating safety with batiraxcept in combination with paclitaxel , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
26 Oct 2023 Status changed from active, no longer recruiting to discontinued.
13 Oct 2023 This trial has been discontinued in Spain According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com